SUNAMITA DA SILVA: Open Payments
NPI 1770069833 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 42 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $61 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $129 |
| ABBVIE INC. | 7 | $125 |
| PFIZER INC. | 5 | $116 |
| GENZYME CORPORATION | 4 | $101 |
| Janssen Biotech, Inc. | 4 | $78 |
| Daiichi Sankyo Inc. | 3 | $74 |
| QOL Medical, LLC | 3 | $69 |
| Ardelyx, Inc. | 2 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
Products named: DUPIXENT, ENTYVIO, TREMFYA, XELJANZ, INJECTAFER, Sucraid, IBSRELA, RINVOQ.
Industry payments across MD — which companies pay providers there.
